GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ovid Therapeutics Inc (NAS:OVID) » Definitions » Degree of Operating Leverage

OVID (Ovid Therapeutics) Degree of Operating Leverage : -0.50 (As of Mar. 2025)


View and export this data going back to 2017. Start your Free Trial

What is Ovid Therapeutics Degree of Operating Leverage?

Degree of Operating Leverage (DOL) measures the percentage change in EBIT for a unit change in Revenue. Ovid Therapeutics's Degree of Operating Leverage for the quarter that ended in Mar. 2025 was -0.50. The higher Degree of Operating Leverage, the higher operating risk the company will take.

The industry rank for Ovid Therapeutics's Degree of Operating Leverage or its related term are showing as below:

OVID's Degree of Operating Leverage is ranked better than
64.89% of 880 companies
in the Biotechnology industry
Industry Median: -0.02 vs OVID: -0.50

Ovid Therapeutics Degree of Operating Leverage Historical Data

The historical data trend for Ovid Therapeutics's Degree of Operating Leverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ovid Therapeutics Degree of Operating Leverage Chart

Ovid Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Degree of Operating Leverage
Get a 7-Day Free Trial Premium Member Only Premium Member Only - -0.16 1.46 -0.09 0.10

Ovid Therapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Degree of Operating Leverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.05 0.14 0.27 0.10 -0.50

Competitive Comparison of Ovid Therapeutics's Degree of Operating Leverage

For the Biotechnology subindustry, Ovid Therapeutics's Degree of Operating Leverage, along with its competitors' market caps and Degree of Operating Leverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ovid Therapeutics's Degree of Operating Leverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ovid Therapeutics's Degree of Operating Leverage distribution charts can be found below:

* The bar in red indicates where Ovid Therapeutics's Degree of Operating Leverage falls into.


;
;

Ovid Therapeutics Degree of Operating Leverage Calculation

Ovid Therapeutics's Degree of Operating Leverage for the quarter that ended in Mar. 2025 is calculated as:

Degree of Operating Leverage=% Change in EBIT**/% Change in Revenue
=( -57.014 (Mar. 2025) / -61.806 (Mar. 2024) - 1 )/( 0.548 (Mar. 2025) / 0.474 (Mar. 2024) - 1 )
=-0.0775/0.1561
=-0.50***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of EBIT and Revenue was used to calculate Degree of Operating Leverage.
*** Please be aware that the Degree of Operating Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Ovid Therapeutics  (NAS:OVID) Degree of Operating Leverage Explanation

Degree of Operating Leverage (DOL) is a leverage ratio that measures the sensitivity of a company’s operting income, also referred to as Earnings Before Interest and Taxes (EBIT), to fluctuations in its Revenue. DOL is a method used to quantify a company’s operating risk. This risk is related to the company's structure of variable costs and fixed costs. Since the fixed costs do not allow the company to adjust the operating costs, the operating risk rises with a higher fixed-to-variable costs proportion.

A high Degree of Operating Leverage indicates that the company’s fixed costs exceed its variable costs. By increasing the sales, the company can earn more profits. In addition, the company must be able to maintain relatively high sales to cover all fixed costs.

Be Aware

The use of operating leverage varies across different industries and business sectors, and the application of Degree of Operating Leverage (DOL) should be adjusted accordingly.


Ovid Therapeutics Degree of Operating Leverage Related Terms

Thank you for viewing the detailed overview of Ovid Therapeutics's Degree of Operating Leverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Ovid Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
441 Ninth Avenue, 14th Floor, New York, NY, USA, 10001
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
Executives
Jeffrey A Rona officer: Chief Business Officer 500 PLAZA DRIVE, SECAUCUS NJ 07094
Jeremy M Levin director, 10 percent owner, officer: CEO
Jason Tardio officer: Chief Commercial Officer 1460 BROADWAY, NEW YORK NY 10036
Takeda Pharmaceuticals U.s.a., Inc. 10 percent owner ONE TAKEDA PARKWAY, DEERFIELD IL 60015
Kevin Joseph Fitzgerald director C/O OVID THERAPEUTICS INC., 1460 BROADWAY, SUITE 15044, NEW YORK NY 10036
Amit Rakhit officer: CMO and PMO C/O OVID THERAPEUTICS INC., 1460 BROADWAY, SUITE 15044, NEW YORK NY 10036
Robert Michael Poole director 200 W. HIGHLAND DR., #303, SEATTLE WA 98119
Takeda Pharmaceutical Co Ltd 10 percent owner 1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU, TOKYO M0 103-8668
Thomas Michael Perone officer: SVP, General Counsel 1460 BROADWAY, NEW YORK NY 10036
Karen Bernstein director C/O VITAE PHARMACEUTICLS, INC., 502 WEST OFFICE CENTER DRIVE, FORT WASHINGTON PA 19034
Millennium Pharmaceuticals Inc 10 percent owner 40 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Douglas E Williams director C/O AMGEN INC, ONE AMGEN CENTER DR, THOUSAND OAKS CA 91320-1799
Ana Ward officer: SVP and General Counsel C/O OVID THERAPEUTICS INC., 1460 BROADWAY, SUITE 15044, NEW YORK NY 10036
Barbara Gayle Duncan director C/O INTERCEPT PHARMACEUTICALS, INC., 18 DESBROSSES STREET, NEW YORK NY 10013
Timothy Daly officer: VP, Finance & Corp. Controller 20 KINGSBRIDGE ROAD, PISCATAWAY NJ 08854